108 unknown. 108 Phase 2, 24 Phase 1, 9 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 108 | Unknown 108 |
| Phase 1 | 24 | Unknown 24 |
| Phase 3 | 9 | Unknown 9 |
Follow Prostate Cancer: new trials by email Literature Review of Prostate Cancer trials Research Report on Prostate Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Impact of Medication Timing Adjustment on the Effect of Novel Hormonal Therapy Receive Abiraterone plus prednisone/Enzalutamide/Apalutamide/Rezvilutamide in the evening - Prostate Cancer | Phase 2 | Unknown | Sun Yat-sen University | 70 | 2024-08-01 | 2024-08-05 |
| Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage Enzalutamide 40 MG, Docetaxel injection - Prostate Cancer, Castrate Resistant Prostate Cancer | Phase 2 / Phase 3 | Unknown | Zhongnan Hospital | 120 | 2024-06-01 | 2024-02-28 |
| To Assess The Patient Preference for Goserelin Microsphere Versus Goserelin Implant in Patients With Prostate Cancer Zoladex, LY01005 - Prostate Cancer | Phase 2 | Unknown | The First Affiliated Hospital of Xiamen University | 60 | 2024-05-01 | 2024-04-26 |
| Study of [177Lu] Lu-XT033 Injection in Patients With Metastatic Prostate Cancer Phase I:[177Lu]Lu-XT033 Injection, Phase II:[177Lu]Lu-XT033 Injection - Prostate Cancer | Phase 1 / Phase 2 | Unknown | Sinotau Pharmaceutical Group | 32 | 2023-09-13 | 2024-05-03 |
| A Phase II Neoadjuvant Study of Darolutamide Plus ADT in Men With Localized Prostate Cancer Darolutamide+ADT - Prostate Cancer | Phase 2 | Unknown | Peking University First Hospital | 53 | 2023-08-05 | 2023-12-12 |
| A Phase 2 Trial of Darolutamide as a Prostate-Specific Membrane Antigen (PSMA) Expression Enhancer in Patients With Localized Prostate Cancer Darolutamide Oral Tablet [Nubeqa] - Prostate Cancer | Phase 2 | Unknown | D'Or Institute for Research and Education | 19 | 2023-07-20 | 2023-08-07 |
| Tracer-Guided Surgery for Recurrent Prostate Cancer PSMA-radioguided surgery, ADT - Prostate Cancer | Phase 2 | Unknown | The Netherlands Cancer Institute | 60 | 2023-02-15 | 2023-10-06 |
| EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC 177Lu-PSMA-617, Ipilimumab, Nivolumab - Prostatic Neoplasms, Genital Neoplasms, Male | Phase 2 | Unknown | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | 93 | 2022-04-29 | 2023-12-15 |
| Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer Leuprolide acetate, Goserelin acetate, Triptorelin acetate - Prostate Cancer | Phase 2 | Unknown | Fudan University | 160 | 2022-04-01 | 2022-03-16 |
| 64Cu-SAR-bisPSMA Positron Emission Tomography of Patients With Known or Suspected Prostate Cancer 64Cu-SAR-bisPSMA - Prostate Cancer | Phase 1 / Phase 2 | Unknown | Luke Nordquist, MD | 150 | 2022-03-28 | 2022-03-18 |
| The Study of Olaparib Combined With Abiraterone and Prednisone in mHSPC Patients With HRR Gene Mutation Olaparib tablet, Abiraterone acetate, Prednisone tablet - Prostate Cancer, Prostate Carcinoma | Phase 2 | Unknown | Hongqian Guo | 30 | 2022-03-01 | 2022-10-25 |
| Efficacy and Safety of Darolutamide Combined With ADT in High-risk/Very High-risk Localized Prostate Cancer Darolutamide 300 mg, Androgen deprivation therapy - Prostate Cancer | Phase 2 | Unknown | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 30 | 2022-01-01 | 2023-01-03 |
| The Study of Olaparib in Newly Diagnosed mCRPC Patients With HRR Gene Mutation Olaparib - Prostate Cancer, Prostate Carcinoma | Phase 2 | Unknown | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 30 | 2021-12-07 | 2022-03-02 |
| A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer Exercise - Exercise, Prostate Cancer | Phase 1 / Phase 2 | Unknown | Kira Murphy | 24 | 2021-09-09 | 2021-12-14 |
| Administration of Antibiotic Prophylaxis for Transperineal Prostate Biopsy in Cipto Mangunkusumo Hospital Cotrimoxazole, Placebo - Prostate Cancer, Prostate Biopsy | Phase 2 | Unknown | Universitas Indonesia | 78 | 2021-07-06 | 2021-08-05 |
| Al18F-PSMA-617 and 68Ga-PSMA-617 PET/CT Imaging in the Same Group of Prostate Cancer Patients Al18F-PSMA-617, 68Ga-PSMA-617 - Prostate Cancer | Phase 2 / Phase 3 | Unknown | Peking Union Medical College Hospital | 100 | 2021-07-01 | 2023-05-03 |
| A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors EU101 - Solid Tumor, Renal Cell Cancer Metastatic | Phase 1 / Phase 2 | Unknown | Eutilex | 110 | 2021-05-31 | 2024-03-15 |
| Neoadjuvant Therapy of Abiraterone Plus ADT for Intraductal Carcinoma of the Prostate Abiraterone acetate, Prednisolone, Goserelin - Prostate Cancer | Phase 2 | Unknown | West China Hospital | 50 | 2021-05-01 | 2021-02-08 |
| Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer Darolutamide, metastasis-directed treatment - Prostate Cancer, Prostate Cancer Recurrent | Phase 2 | Unknown | University Hospital, Ghent | 124 | 2021-02-12 | 2024-02-28 |
| Phase II Study of the Use of Neoadjuvant Cabazitaxel With Hormonal Treatment in Patients Operable Prostate Cancer, Assess the Efficacy and Toxicity of Cabazitaxel, and Explore Potential Predictive and Prognostic Markers of Clinical Outcome Cabazitaxel - Prostate Cancer | Phase 2 | Unknown | The Clatterbridge Cancer Centre NHS Foundation Trust | 120 | 2021-01-15 | 2021-01-05 |
Showing 20 of 108. Sign in to see all of them.
Prostatic Neoplasms (108) · Neoplasms (7) · Carcinoma, Non-Small-Cell Lung (4) · Neoplasm Metastasis (4) · Breast Neoplasms (3) · Prostatic Diseases (3) · Stomach Neoplasms (3) · Genital Neoplasms, Male (2) · Neoplasms by Site (2) · Pain (2) · Pancreatic Neoplasms (2) · Urogenital Neoplasms (2) · Adenoviridae Infections (1) · Alzheimer Disease 5 (1) · Atrial Fibrillation (1)
Genital Diseases (108) · Male Urogenital Diseases (108) · Urogenital Diseases (108) · Genital Diseases, Male (107) · Genital Neoplasms, Male (106) · Neoplasms by Site (106) · Urogenital Neoplasms (106) · Prostatic Diseases (105) · Neoplasms (101) · Pathological Conditions, Signs and Symptoms (9) · Pathologic Processes (7) · Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Neoplastic Processes (5) · Bronchial Neoplasms (4)
Docetaxel (8) · Abiraterone Acetate (7) · Goserelin (6) · Radiosurgery (6) · Prednisone (5) · enzalutamide (5) · Estramustine (3) · Gonadotropin-Releasing Hormone (3) · Radiotherapy (3) · acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide (3) · apalutamide (3) · bicalutamide (3) · darolutamide (3) · Androgen Antagonists (2) · Brachytherapy (2)
Sunnybrook Health Sciences Centre (3) · University College London Hospitals (3) · Department of Veterans Affairs, New Jersey (2) · Fudan University (2) · Peking Union Medical College Hospital (2) · Radboud University Medical Center (2) · Roll International Corporation (2) · Royal Marsden NHS Foundation Trust (2) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (2) · Universitaire Ziekenhuizen KU Leuven (2) · University of Toronto (2) · West China Hospital (2) · AHS Cancer Control Alberta (1) · Adamis Pharmaceuticals Corporation (1) · Alberta Health services (1)
United States (28) · China (17) · Canada (13) · United Kingdom (8) · Australia (4) · Belgium (4) · Netherlands (4) · Brazil (3) · France (3) · Egypt (2) · Israel (2) · Italy (2) · Singapore (2) · Spain (2) · Croatia (1)
Allan J Pantuck, MD (2) · Arie S Belldegrun, MD (2) · Basil Kasimis, MD (2) · Laurence Klotz, MD (2) · Mark Emberton, MD, FRCS, MBBS (2) · Michiel Sedelaar, MD, PhD (2) · Abolfazl Razzaghdoust (1) · Alfonso Gomez-Iturriaga, MD (1) · Alfonso Gomez-Iturriaga, MD, PhD (1) · Andrew Loblaw, MD (1) · Andrew Loblaw, MD, FRCPC (1) · Bernard Fox, PhD (1) · Bernhard Eigl, M.D. (1)
PMID 15042609, PMID 17587390, PMID 19091394, PMID 19286225, PMID 19308068, PMID 21470407, PMID 22056152, PMID 22500211, PMID 22614062, PMID 22866066, PMID 22932804, PMID 23619389, PMID 24290503, PMID 24321502, PMID 24412228, PMID 24464861, PMID 24472709, PMID 24821581, PMID 25217422, PMID 25566502, PMID 25682339, PMID 25819287, PMID 26215782, PMID 27150293, PMID 27296781, PMID 27836248, PMID 28498618, PMID 29153462, PMID 29606109, PMID 30528653, PMID 30545809, PMID 33203399, PMID 34350976, PMID 34557930, PMID 35396138, PMID 35780048, PMID 36723911, PMID 36727866, PMID 37435500, PMID 38172595, PMID 38176721, PMID 38421252, PMID 39095735, PMID 39751962, PMID 40287937, PMID 40540036, PMID 42115448
2016 (2), 2017 (1), 2019 (1)